Compare IPCA Labs with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DR. REDDYS LAB - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DR. REDDYS LAB IPCA LABS/
DR. REDDYS LAB
 
P/E (TTM) x 26.0 18.7 139.2% View Chart
P/BV x 5.0 3.6 139.1% View Chart
Dividend Yield % 0.2 0.7 36.9%  

Financials

 IPCA LABS   DR. REDDYS LAB
EQUITY SHARE DATA
    IPCA LABS
Mar-19
DR. REDDYS LAB
Mar-19
IPCA LABS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,0422,875 36.2%   
Low Rs5901,888 31.3%   
Sales per share (Unadj.) Rs298.6930.2 32.1%  
Earnings per share (Unadj.) Rs35.0117.4 29.8%  
Cash flow per share (Unadj.) Rs49.4185.8 26.6%  
Dividends per share (Unadj.) Rs3.0020.00 15.0%  
Dividend yield (eoy) %0.40.8 43.8%  
Book value per share (Unadj.) Rs247.1844.4 29.3%  
Shares outstanding (eoy) m126.35166.07 76.1%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.72.6 106.7%   
Avg P/E ratio x23.320.3 115.0%  
P/CF ratio (eoy) x16.512.8 128.8%  
Price / Book Value ratio x3.32.8 117.1%  
Dividend payout %8.617.0 50.3%   
Avg Mkt Cap Rs m103,108395,496 26.1%   
No. of employees `00013.422.0 61.2%   
Total wages/salary Rs m7,87433,562 23.5%   
Avg. sales/employee Rs Th2,807.07,032.8 39.9%   
Avg. wages/employee Rs Th585.81,527.9 38.3%   
Avg. net profit/employee Rs Th329.0887.7 37.1%   
INCOME DATA
Net Sales Rs m37,732154,482 24.4%  
Other income Rs m5773,375 17.1%   
Total revenues Rs m38,309157,857 24.3%   
Gross profit Rs m6,90131,782 21.7%  
Depreciation Rs m1,82411,348 16.1%   
Interest Rs m189889 21.2%   
Profit before tax Rs m5,46522,920 23.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0423,858 27.0%   
Profit after tax Rs m4,42219,500 22.7%  
Gross profit margin %18.320.6 88.9%  
Effective tax rate %19.116.8 113.3%   
Net profit margin %11.712.6 92.8%  
BALANCE SHEET DATA
Current assets Rs m23,778111,101 21.4%   
Current liabilities Rs m10,97558,973 18.6%   
Net working cap to sales %33.933.7 100.6%  
Current ratio x2.21.9 115.0%  
Inventory Days Days10479 130.8%  
Debtors Days Days6694 70.0%  
Net fixed assets Rs m20,368101,245 20.1%   
Share capital Rs m253830 30.4%   
"Free" reserves Rs m30,971139,406 22.2%   
Net worth Rs m31,224140,236 22.3%   
Long term debt Rs m1,40922,000 6.4%   
Total assets Rs m45,507224,656 20.3%  
Interest coverage x30.026.8 111.9%   
Debt to equity ratio x00.2 28.8%  
Sales to assets ratio x0.80.7 120.6%   
Return on assets %10.19.1 111.6%  
Return on equity %14.213.9 101.9%  
Return on capital %17.314.9 115.9%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30888,673 19.5%   
Fx outflow Rs m6,26619,104 32.8%   
Net fx Rs m11,04269,569 15.9%   
CASH FLOW
From Operations Rs m4,92328,704 17.2%  
From Investments Rs m-1,563-7,727 20.2%  
From Financial Activity Rs m-1,832-21,326 8.6%  
Net Cashflow Rs m1,528-314 -486.5%  

Share Holding

Indian Promoters % 45.9 25.5 180.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.4 211.1%  
FIIs % 25.3 35.3 71.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.4 15.3 113.7%  
Shareholders   36,892 75,885 48.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALKEM LABORATORIES  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Scales 42,000 and Smallcaps Rebound: What Happens Next?(Podcast)

This week, the BSE Sensex crossed 42,000 level for the first time. While Nifty followed suit, hitting a record high of 12,377.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Jan 6, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

I Made a Killing in the Markets this Week... Here's How(Profit Hunter)

Jan 10, 2020

How we made a killing in the markets amidst geopolitical tension and war mongering.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 17, 2020 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS